Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies
نویسندگان
چکیده
منابع مشابه
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.
BACKGROUND Stopping smoking is associated with many important improvements in health and quality of life. The use of cessation medications is recommended to increase the likelihood of quitting. However, there is historical and renewed concern that smoking cessation therapies may increase the risk of cardiovascular disease events associated within the quitting period. We aimed to examine whether...
متن کاملThe effect of five smoking cessation pharmacotherapies on smoking cessation milestones.
OBJECTIVE Most smoking cessation studies have used long-term abstinence as their primary outcome measure. Recent research has suggested that long-term abstinence may be an insensitive index of important smoking cessation mechanisms. The goal of the current study was to examine the effects of 5 smoking cessation pharmacotherapies using Shiffman et al.'s (2006) approach of examining the effect of...
متن کاملThe use of pharmacotherapies for smoking cessation during pregnancy.
A workshop entitled “The use of pharmacotherapies for smoking cessation during pregnancy”, sponsored by the National Institute of Child Health and Human Development (NICHD) and the Robert Wood Johnson Foundation (RWJF), was held in Rockville, Maryland, on 19 May 1999. The goals of the workshop were: (1) to determine the current state of knowledge related to the use of pharmacotherapies for smok...
متن کاملFactors associated with smoking cessation
OBJECTIVE To analyze the prevalence and factors associated with smoking abstinence among patients who were treated in a reference unit for smoking cessation. METHODS This cross-sectional study examined the medical records of 532 patients treated in a reference unit for smoking cessation in Belém, PA, Northern Brazil, between January 2010 and June 2012. Sociodemographic variables and those relat...
متن کاملVarenicline, smoking cessation, and neuropsychiatric adverse events.
OBJECTIVE In 2009, the U.S. Food and Drug Administration issued a black box warning for varenicline regarding neuropsychiatric events. The authors used data from randomized controlled trials and from a large Department of Defense (DOD) observational study to assess the efficacy and safety of varenicline. METHOD The authors reanalyzed data from the 17 placebo-controlled randomized controlled t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2014
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.113.003961